| __timestamp | Rhythm Pharmaceuticals, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1213000 | 72471000 |
| Thursday, January 1, 2015 | 3425000 | 89204000 |
| Friday, January 1, 2016 | 6311000 | 106010000 |
| Sunday, January 1, 2017 | 9518000 | 137905000 |
| Monday, January 1, 2018 | 28080000 | 159888000 |
| Tuesday, January 1, 2019 | 36550000 | 158425000 |
| Wednesday, January 1, 2020 | 46125000 | 200677000 |
| Friday, January 1, 2021 | 68486000 | 304759000 |
| Saturday, January 1, 2022 | 92032000 | 377221000 |
| Sunday, January 1, 2023 | 117532000 | 336361000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, effective cost management is crucial. Rhythm Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. offer a compelling study in contrasting strategies over the past decade. From 2014 to 2023, Rhythm Pharmaceuticals saw a staggering 9,600% increase in their Selling, General, and Administrative (SG&A) expenses, reflecting their aggressive growth and expansion efforts. In contrast, Supernus Pharmaceuticals experienced a more modest 360% rise, indicating a steady, controlled approach to scaling operations.
By 2023, Supernus Pharmaceuticals' SG&A expenses were nearly three times higher than Rhythm's, highlighting their larger operational scale. However, Rhythm's rapid increase suggests a strategic pivot towards capturing market share. This data underscores the diverse strategies companies employ to balance growth and cost management, offering valuable insights for investors and industry analysts alike.
Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Incyte Corporation and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Summit Therapeutics Inc. vs Rhythm Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Ascendis Pharma A/S and Rhythm Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Supernus Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Bausch Health Companies Inc. or Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Vericel Corporation and Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Supernus Pharmaceuticals, Inc. or Wave Life Sciences Ltd.
Supernus Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends